157 related articles for article (PubMed ID: 36442427)
21. The Functional Role and Regulatory Mechanism of FTO m
Yang Q; Al-Hendy A
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175660
[TBL] [Abstract][Full Text] [Related]
22. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
23. MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness.
Gonzalez-Molina J; Hahn P; Falcão RM; Gultekin O; Kokaraki G; Zanfagnin V; Braz Petta T; Lehti K; Carlson JW
Mol Oncol; 2024 Apr; 18(4):850-865. PubMed ID: 37078535
[TBL] [Abstract][Full Text] [Related]
24. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
25. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma.
Yang Q; Bariani MV; Falahati A; Khosh A; Lastra RR; Siblini H; Boyer TG; Al-Hendy A
Cells; 2022 Jul; 11(14):. PubMed ID: 35883603
[TBL] [Abstract][Full Text] [Related]
26. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
27. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
28. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
29. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma.
Zhang P; Zhang H; Wang Y
Cell Tissue Res; 2021 Feb; 383(2):865-879. PubMed ID: 33151453
[TBL] [Abstract][Full Text] [Related]
30. Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Jeong SY; Cho YJ; Ryu JY; Choi JJ; Hwang JR; Kim B; Lee YY; Kim HS; Lee JW
Gynecol Oncol; 2021 Jul; 162(1):173-181. PubMed ID: 33972086
[TBL] [Abstract][Full Text] [Related]
31. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Ingham M; Allred JB; Chen L; Das B; Kochupurakkal B; Gano K; George S; Attia S; Burgess MA; Seetharam M; Boikos SA; Bui N; Chen JL; Close JL; Cote GM; Thaker PH; Ivy SP; Bose S; D'Andrea A; Marino-Enriquez A; Shapiro GI; Schwartz GK
J Clin Oncol; 2023 Sep; 41(25):4154-4163. PubMed ID: 37467452
[TBL] [Abstract][Full Text] [Related]
32. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile.
Astolfi A; Nannini M; Indio V; Schipani A; Rizzo A; Perrone AM; De Iaco P; Pirini MG; De Leo A; Urbini M; Secchiero P; Pantaleo MA
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751892
[TBL] [Abstract][Full Text] [Related]
33. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
34. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
[TBL] [Abstract][Full Text] [Related]
35. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
36. [The loss of heterozygosity and microsatellite instability analysis in differential diagnostics of leiomyosarcoma and proliferative leiomyoma of the uterus].
Shikeeva AA; Kekeeva TV; Zavalishina LÉ; Andreeva IuIu; Frank GA
Arkh Patol; 2011; 73(4):47-50. PubMed ID: 22164433
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing‑based approach.
Yoshida K; Yokoi A; Kitagawa M; Sugiyama M; Yamamoto T; Nakayama J; Yoshida H; Kato T; Kajiyama H; Yamamoto Y
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36929268
[TBL] [Abstract][Full Text] [Related]
38. Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.
Arend RC; Toboni MD; Montgomery AM; Burger RA; Olawaiye AB; Monk BJ; Herzog TJ
Oncologist; 2018 Dec; 23(12):1533-1545. PubMed ID: 30139839
[TBL] [Abstract][Full Text] [Related]
39. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
40. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
Mei L; Zhang J; He K; Zhang J
J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
